Posted by Michael Wonder on 08 Oct 2024
Bimekizumab for the treatment of patients with moderate to severe hidradenitis suppurativa
7 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use of bimekizumab in the NHS in England.
For the time being, bimekizumab is not recommended for the treatment of adults with active moderate to severe hidradenitis suppurativa (acne inversa) that has not responded well enough to conventional systemic treatment.
